Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Eternity Healthcare Inc. (OTCBB:ETAH), a medical device and diagnostic company specializing in diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood. The technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

"Eternity Healthcare will be the first company to focus on the development of an alternative saliva-based glucose monitoring test. Using two parameters of diabetes physiological changes, the device will provide more accurate results for diabetics and their blood sugar levels. This new test should reduce the patient's reliance on the currently used painful finger pricking and blood collection method," commented Dr. Hassan Salari, CEO.

Major marketers of glucose monitoring devices are big pharmaceutical companies, including Abbott Diabetic Care Inc., Bayer Healthcare, AG LifeScan Inc., Roche Diagnostics Corp., Medtronic Inc., DexCom Inc. and more. According to the Center for Disease Control, over 10 million glucose monitor devices and several hundred million of test strips are sold annually. The global blood glucose monitoring devices market was US$8.9 billion in 2010. The worldwide glucose monitoring devices market is expected to be US$16 billion by 2014.